Company profile for Alar Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs. Long-acting r...
Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs. Long-acting release product is a solution to improve medical quality, enhance patient’s compliance, and increase drug adherence.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Taiwan
Address
Address
Rm. 312, 3F., No. 19, Keyuan Rd., Xitun Dist., Taichung City 407, (R.O.C.)
Telephone
Telephone
+886-4-24637115
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/alar-pharmaceuticals-announces-first-patient-dosing-in-a-study-of-ala-3000-extended-release-ketamine-injection-for-treatment-resistant-depression-trd-302454659.html

PR NEWSWIRE
14 May 2025

https://www.prnewswire.com/news-releases/alar-announces-significant-progress-on-developing-long-acting-buprenorphine-injectable-ala-1000-301459457.html

PRNEWSWIRE
12 Jan 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty